Loading...
XNAS
NEO
Market cap303mUSD
Dec 05, Last price  
11.90USD
1D
-2.22%
1Q
49.12%
Jan 2017
38.86%
IPO
296.67%
Name

Neogenomics Inc

Chart & Performance

D1W1MN
XNAS:NEO chart
P/E
P/S
0.46
EPS
Div Yield, %
Shrs. gr., 5y
-24.55%
Rev. gr., 5y
10.07%
Revenues
661m
+11.65%
1,885,3246,475,99611,504,72520,015,31929,469,05434,371,00043,484,00059,867,00066,467,00087,069,00099,802,000244,083,000258,611,000276,741,000408,830,000444,448,000484,329,000509,728,000591,643,000660,566,000
Net income
-79m
L-10.51%
-997,160-129,661-3,380,172-1,382,586-2,242,813-3,303,000-1,177,00065,0002,033,0001,132,000-2,535,000-5,723,000-846,0002,640,0008,006,0004,172,000-8,347,000-144,250,000-87,968,000-78,726,000
CFO
7m
P
-902,051-693,782-2,642,591-138,306-1,500,417-2,052,00069,000-492,0002,227,0009,450,0006,393,00021,477,00018,037,00044,786,00023,369,0001,460,000-26,723,000-65,993,000-1,953,0007,023,000
Dividend
Dec 17, 20200.4 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
IPO date
Dec 10, 2012
Employees
2,100
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT